US lawmakers blast patent thickets in letter to USPTO director

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US lawmakers blast patent thickets in letter to USPTO director

retro banner with red vintage typewriter with a blank sheet of p

Three Republican and two Democratic Congress members have claimed that patent thickets hinder access to affordable medicine

Members from both sides of the US House of Representatives wrote to USPTO director Kathi Vidal on Friday, March 24, expressing their concern about “patent thicketing.”

Five members – three Republicans and two Democrats – urged Vidal to consider implementing the proposed policies outlined in her October 4 2022 request for comment.

Vidal’s suggested that parties seeking to overcome rejections based on obvious variations of prior claims should stipulate that those claims aren’t patentably distinct.

Such admission would ensure that if one of the duplicates was invalidated, courts could consider that fact as evidence against the others, the members claimed.

“Branded manufacturers will often seek numerous patents on a single feature of a drug, creating a dense web, or thicket, of patents that delay generic and biosimilar competition,” the letter said.

“While some may question the quality of these patents, the high cost, uncertainty, and lengthy process for challenging them, makes it practically impossible to sort the good from the bad.”

The letter added that patent thickets, the process of seeking multiple patents on a single feature of drug, protected older drugs from competition, which costs the US government and taxpayers more money and hinders patients’ options for cost-effective treatment.

The signees were Republican Jodey Arrington, Michael Burgess and Darrell Issa, and Democrats Lloyd Doggett and Annie Kuster.

Vidal’s October 2022 request for comment came about after President Joe Biden issued an executive order to promote access to drugs in 2021 and after six senators raised concerns about patent thickets in a June 2022 letter to the USPTO.

more from across site and SHARED ros bottom lb

More from across our site

Alston & Bird acted for InterDigital, while Samsung was represented by Fish & Richardson, during the arbitration process
Powell Gilbert lawyers reveal how they navigated parallel EPO proceedings and collaborated with European peers to come out on top in the Nordic-Baltic Division’s first judgment
The firms posted increases in revenue and profit per equity partner, with both giving a nod to their IP expertise
EasyGroup, the owner of the easyJet airline, said in a press release that UK-based first-instance judges are “less experienced”, bringing a long-running debate back to the fore
A cross-practice team from Mayer Brown, which included members of the firm’s IP practice, advised on the deal
María Cecilia Romoleroux discusses the challenges she has faced in her career in IP and how she hopes to improve things for the next generation of women
Value-added services give in-house counsel the satisfaction that they are getting more value for money, while law firms get the opportunity to win more work
A team at Boies Schiller Flexner is advising shoe company Kizik and parent company HandsFree Labs in the dispute
Nokia’s latest enforcement actions against Geely and Transsion joining Via LA’s AAC pool were also among the top talking points
Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Gift this article